Dr. Reddy's Pharmaceutical Company Commences Operations in Philippines. Expands presence in the ASEAN region
Dr.Reddy’s pharmaceutical company has expanded its presence in the ASEAN region with the opening of its 41st overseas office in Manila, Philippines in partnership with Britton Marketing Corporation, a sister company of Britton Distributions, Inc. This distributor-based model will serve the US $1.8 billion Philippines pharmaceutical market, which is growing at over 10% annually.
The pharmaceutical company is initially targeting therapeutic areas like cardiology, diabetology, gastroenterology and pain management. The first phase of launch will see major brands like Omez(Omeprazole), Stamlo M(Amlodipine maleate), Resilo (Losartan) ,Reclide(Gliclazide), Cardiopril(Ramipril), Rafree(Meloxicam), Ciprolet(Ciprofloxacin), and Finast(Finasteride) being introduced in the Philippines market.
Commenting on the opening of the new office, Rajesh Kumar, Head- AMEEERA region said,
“Accessibility of quality and affordable medicines is among the pressing issues in Philippines today. It is one of the key markets in the ASEAN region for us and being a leader in the generics space, Dr. Reddy’s has a lot to offer to the Filipino medical community and the people of Philippines. BMC has a strong marketing presence in the healthcare products market and together with Dr. Reddy’s, is ideally placed to serve this market”.
Notes to the editor:
The Branded Formulations Business of Dr Reddy’s operates from six geographic regions: India & SAARC, Russia & CIS countries, China, Latin America, South Africa & AMEERA (Asean Middle East Eastern Europe Rest of Africa)
In ASEAN, Dr. Reddy’s already has presence in Myanmar, Vietnam, Cambodia, Malaysia, Singapore, and Thailand
About Dr. Reddy's:
Established in 1984, Dr. Reddy's Laboratories (NYSE: RDY) is an emerging global pharmaceutical company with proven pharmaceutical research capabilities. The Company is vertically integrated with a presence across the pharmaceutical value chain. It produces finished dosage forms, active pharmaceutical ingredients and biotechnology products and markets them globally, with focus on India, US, Europe and Russia. The Company conducts research in the areas of diabetes, cardiovascular and cancer.
www.drreddys.com
Contact Information:
Investors and Financial Analysts:
Nikhil Shah at nikhilshah@drreddys.com or on +91-40-23731946 ext. 308
Media:
M Mythili at mythilim@drreddys.com or on +91-40-66511620
Website: www.drreddys.com
|
Share: